- Generation of a novel database of naturally presented and immunogenic Merkel cell carcinoma (MCC) epitopes identified directly from primary MCC samples using the proprietary technology platform XPRESIDENT™ based on high-sensitivity mass spectrometry (WP3).
- In vivo validation of selected naturally presented MCC epitopes by describing their immunogenicity in a multicenter immunotherapy trial with F16-IL2 (WP4).
- Coordination of the standardized collection of high-quality peripheral blood cell samples.
- Participation in WP7, identification of new cellular markers and potential surrogates for immunological efficacy of F16-IL2.
Expertise relevant to the proposed work:
immatics biotechnologies is a clinical-stage biopharmaceutical company based in Tuebingen and Munich, Germany, developing advanced therapeutic vaccines that are active against cancer. immatics’ lead product, IMA901, is in a pivotal phase 3 study after completing a successful phase 2 trial in renal cell carcinoma. immatics’ pipeline also includes IMA910 which has completed a phase 2 study in colorectal cancer and IMA950 which is in two phase 1 studies for glioblastoma. immatics’ technology platform XPRESIDENT™ rapidly generates defined therapeutic cancer vaccines which are based on multiple tumor-associated peptides (TUMAPs) with the ability to specifically stimulate the immune system against cancer cells. These vaccines – comprising multiple peptides confirmed to be naturally presented by real tumor tissue – offer the prospect of greater effectiveness than existing therapeutic approaches combined with fewer side effects. This approach represents a very specific, clinically promising and commercially scalable approach in cancer vaccines. immatics has established centralized, standardized and validated immunomonitoring for their completed and ongoing multi-centric clinical trials. As immunomonitoring is an active field of research by itself, immatics is collaborating with two international leading organizations, the Association of Cancer Immunotherapy (CIMT, Europe) and the Cancer Immunotherapy Consortium (CRI-CIC, USA). Based on this immunomonitoring platform, immatics was able to show that both completed phase 2 trials IMA901 and IMA910 indicate a consistent association between immune response to IMA901 or IMA910 respectively and all clinical endpoints.
immatics’ specific role in the project:
- participation in WP3, 4, 5, and 7
- conduction of research on naturally presented T cell epitope identification
- leading of WP4, coordination of the standardized collection of high quality PBMC from patients, and execution of the immunomonitoring of MCC patients treated within the clinical trial
- involvement in the identification of new cellular markers as well as in WP7